Skip to content

A Global Active Surveillance for Community Acquired Pneumonia

Global Active Surveillance for Community-Acquired Pneumonia (CAP) in Adults 50 Years and Older

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00929721
Enrollment
5172
Registered
2009-06-29
Start date
2009-12-31
Completion date
2012-02-29
Last updated
2012-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Community Acquired Pneumonia

Keywords

CAP

Brief summary

This study is an observational surveillance study to identify adults 50 years and older who present to a study healthcare facility with signs and symptoms of Community-Acquired Pneumonia.

Interventions

PROCEDUREBlood draw

culture for Streptococcus pneumoniae Frequency-1

PROCEDUREChest X-ray

image of the lungs to assess changes consistent with pneumonia Frequency-1

assay for the presence of Streptococcus pneumoniae Binax and UAD

PROCEDURENasopharyngeal swab

culture for Streptococcus pneumoniae Frequency-1

PROCEDUREsputum

culture for Streptococcus pneumoniae Frequency-1

Sponsors

Pfizer
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult subjects 50 years of age or older * Subject must reside in the surveillance area * Subjects who present to a study healthcare facility where the treating physician clinically suspects CAP

Exclusion criteria

* Any subject who is transferred to a study healthcare facility after already being hospitalized for 48 hours or more at any other in-patient facility (such as a community hospital). * Hospital Acquired pneumonia (ie, develops signs and symptoms of pneumonia after being hospitalized for 48 hours or more).

Design outcomes

Primary

MeasureTime frame
Incidence rates of CAP in adults 50 years and olderup to 120 days from enrollment

Secondary

MeasureTime frame
Frequency of bacterial agents associated with CAP, Case fatality and incidence rates of CAP number and characteristics of subjects from outpatient clinics, emergency rooms, and hospital in-patient departmentsup to 120 days from enrollment

Countries

Poland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026